Keith Goldan

[Syndax @Syndax]

On #WorldBloodCancerDay, we shine a light on the importance of expanding access to novel therapies for patients in need. #DYK that most new therapies approved for adults are not tested in children, and for cancer drugs, the average delay between the first clinical trial in adults to the first clinical trial in children is 6.5 years?

Together, we have partnered with @BloodCancerUtd to expand clinical trial access for historically excluded patient groups, including pediatrics.

Learn about what’s possible when science, courage and pediatric patient advocacy come together by watching the below video.

#PassionforPatients

[Syndax @Syndax]

#NewsAlert: Today, we reported our fourth quarter and full year 2025 financial results and provided a business update.

We solidified our leadership position and proved the strength of Syndax’s R&D and commercial capabilities in 2025, achieving our third FDA approval and successfully launching two first-in-class medicines. Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) have made an impact for thousands of patients and generated over $170 million in revenue to Syndax in 2025, advancing the company towards profitability.

With strong momentum and multiple growth drivers for both products, Syndax is well positioned for continued growth in 2026 and beyond.

Learn more by reading our press release and joining our conference call today at 4:30 p.m. ET:
https://t.co/86U4a4LT87

A live replay will be available after the call for a limited time.

[The White House @WhiteHouse]

Proud to be an American. 🇺🇸🇺🇸

[Syndax @Syndax]

#MarkYourCalendars: Join us for a conference call and webcast on Thursday, February 26 at 4:30 p.m. ET to hear the Syndax team discuss our fourth quarter and full year 2025 financial results and provide a business update.

Click the link below for more details:
https://t.co/rR5lzZKNMb

A live replay will be available after the call.

[Syndax @Syndax]

#NewsAlert: Today, we announced preliminary, unaudited fourth quarter and full year 2025 financial results and provided additional business updates ahead of our presentation at the 44th Annual J.P. Morgan Healthcare conference.

2025 was a transformational year for Syndax as we secured our third FDA approval and successfully executed the launches of Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), proving our ability to deliver innovative therapies for patients and advancing the company towards profitability.

With strong momentum and further acceleration of growth going into 2026, we look forward to continuing to build Revuforj and Niktimvo into industry leading franchises and advancing our clinical development programs designed to expand our patient impact and unlock the multi-billion-dollar potential of both medicines.

Join the webcast at 3:00 p.m. PT/6:00 p.m. ET to learn more:
https://t.co/aXrpeB1ljr

A live replay will be available for a limited time.

[John Stossel @JohnStossel]

For years, Europe’s economy was about the size of America’s. Not today.

Today, the U.S. is 50% RICHER--despite the EU having 100 million MORE people.

What changed?

[Syndax @Syndax]

#NewsAlert: Throughout #ASH25, we’ve presented compelling data across our Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) programs.

Today, we’re highlighting key Revuforj presentations spanning the treatment continuum.

View the press release and tune in to our upcoming investor event at a.m. ET / a.m. PT to learn more: https://t.co/R3MvzqOj3c

A live replay will be available for a limited time.

[Syndax @Syndax]

#MarkYourCalendars: On Monday, December 8 at 7:00 a.m. ET, Syndax will host an investor event during the 67th American Society of Hematology (#ASH25) Annual Meeting.

Members of the Syndax management team will be joined by multiple key opinion leaders to discuss data updates from the revumenib and axatilimab-csfr programs.

Catch all the details below:
https://t.co/Os1gzgmT3V

A live replay will be available for a limited time.

[Syndax @Syndax]

#NewsAlert: Today, we reported our third quarter 2025 financial results and provided a business update.

The third quarter was another remarkable period of commercial and pipeline execution for Syndax. Demand remained strong for Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) with over $75 million in combined net sales for the quarter.

We also furthered our leadership in menin inhibition with the latest addition to the clinical practice guidelines in late September followed by FDA approval in late October. Our expansion into this second indication is underway and we are making great progress driving awareness and generating demand.

Learn more by reading our press release and joining our conference call today at 4:30 p.m. ET:
https://t.co/tWasV0vY4O

A live replay will be available after the call for a limited time.

[Syndax @Syndax]

#NewsAlert: We are thrilled to announce another major milestone for Syndax. The U.S. Food and Drug Administration (FDA) has now approved a second indication for revumenib.

We would like to extend our sincere appreciation to the clinicians, investigators, Syndax employees, and patients who made this achievement possible.

Learn more by reading our press release and tuning in to our live webcast today at 2:30 p.m. ET:
https://t.co/AqfipOanWR

A replay will be available after the call.

#FDAApproval #WeFlyHigherTogether

[FBI Salt Lake City @FBISaltLakeCity]

We are asking for the public's help identifying this person of interest in connection with the fatal shooting of Charlie Kirk at Utah Valley University.
1-800-CALL-FBI
Digital media tips: https://t.co/K7maX81TjJ

[Syndax @Syndax]

#NewsAlert: Today, we reported our first quarter 2025 financial results and provided a business update.

This was an outstanding quarter in which Revuforj and Niktimvo generated a combined $34 million in net sales. We believe this success is a reflection of excellent commercial execution and the clinical profile of these first- and best-in-class medicines.

We’ve also made excellent progress advancing our pipeline, including most notably the recent submission of our sNDA for R/R mNPM1 AML and the initiation of the first pivotal frontline trial of a menin inhibitor in combination with venetoclax and azacitidine for mNPM1 and KMT2Ar AML.

Learn more by reading our press release and joining our conference call today at 4:30 p.m. ET:
https://t.co/v0BuWACjFT

A live replay will be available after the call for a limited time.

[Syndax @Syndax]

#MarkYourCalendars: Join us for a conference call and webcast on Monday, May 5 at 4:30 p.m. ET to hear the Syndax team discuss our first quarter 2025 financial results and provide a business update.

Click the link below for more details:
https://t.co/nBb6np4DqF

A live replay will be available after the call.

[OutKick @Outkick]

Maine's state Speaker of the House silences @laurel_libby for defending women

@Riley_Gaines_

[Keith Goldan @keithgoldan]

@TuckerCNews AAAAA

[Syndax @Syndax]

#NewsAlert: Ahead of our presentation at #JPM2025 on Tuesday, January 14, we are pleased to share our recent accomplishments and anticipated 2025 milestones.

This year, we are focused on executing two outstanding U.S. launches for our first-in-class medicines. We believe that Syndax is well-positioned for continued success and long-term growth with two approved drugs launching into multi-billion-dollar markets, a clear strategy to expand into additional indications and earlier lines of treatment, & a strong cash position expected to fund operations through profitability.

Learn more by reviewing our latest press release: https://t.co/9dOwn8FrhR

Or by tuning in to our fireside chat tomorrow at 10:30 a.m. PT/1:30 p.m. ET: https://t.co/4StH7ZusTr

[Blood Cancer United @BloodCancerUtd]

The @US_FDA has approved a first-of-its-kind therapy for adults and children one year and older with advanced AML. LLS proudly supports this research and leads initiatives like Beat AML® and PedAL to advance safer, targeted treatments. Get the details 👉 https://t.co/foM0Bo1ljh #leusm

[Syndax @Syndax]

#NewsAlert: Today, we announced updated positive data from the BEAT AML trial in combination with venetoclax and azacitidine in newly diagnosed AML patients and additional data from the AUGMENT-101 trial in relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (#AML).

View the press release & tune in to our upcoming investor event at 10:00 a.m. ET / 7:00 a.m. PT to learn more:

https://t.co/XLVhndDCvQ

https://t.co/BrYiwIurOJ

#ASH24

[Syndax @Syndax]

#MarkYourCalendars: On Monday, December 9, members of the Syndax management team will be joined by multiple key opinion leaders to discuss data updates from the Company's revumenib and axatilimab-csfr programs during our annual #ASH24 investor event.

Access dial-in details below:
https://t.co/8sr0oPCXTt

A replay of the event will be available for a limited time.

[Syndax @Syndax]

#NewsAlert: We are thrilled to announce a major milestone for Syndax. The U.S. Food and Drug Administration (FDA) has now approved the first and only therapy for relapsed or refractory acute leukemia with a KMT2A translocation.

We would like to extend our heartfelt gratitude to the clinicians, investigators, Syndax employees, and patients who made this achievement possible.

Learn more by reading our press release and tuning in to our live webcast today at 6:00 p.m. ET: https://t.co/Q2x5jORGOf

A replay will be available after the call.

#FDAApproval #WeFlyHigherTogether